Shorts

Can GLP-1 drugs lower cancer risk?
0:59
Can GLP-1 drugs lower cancer risk?
4 hours ago
by
Jennifer Ligibel, MD
Neoantigen Vaccines Signal A New Arm of Cancer Immunotherapy
0:55
Neoantigen Vaccines Signal A New Arm of Cancer Immunotherapy
2 days ago
by
Karen E. Knudsen, MBA, PHD
RWD: Closing Gaps in Guideline-Based Oncology Care
0:31
RWD: Closing Gaps in Guideline-Based Oncology Care
3 days ago
by
Ravi Parikh, MD, MPP
KRAS G12D Inhibitor Combos Advance in Pancreatic Cancer
0:32
KRAS G12D Inhibitor Combos Advance in Pancreatic Cancer
8 days ago
by
Shubham Pant, MD, MBBS
Encouraging Healthy Weight Loss in Patients With Cancer
0:46
Encouraging Healthy Weight Loss in Patients With Cancer
9 days ago
by
Sai Yendamuri, MD, MBA, FACS
Why Explore Vaccines After Pancreatic Cancer Surgery?
0:57
Why Explore Vaccines After Pancreatic Cancer Surgery?
10 days ago
by
Shubham Pant, MD, MBBS
Is the future of pancreatic cancer finally shifting away from chemotherapy?
0:17
Is the future of pancreatic cancer finally shifting away from chemotherapy?
12 days ago
by
Zev A. Wainberg, MD
Pancreatic Cancer Vaccine Findings Warrant Further Study
1:11
Pancreatic Cancer Vaccine Findings Warrant Further Study
14 days ago
by
Shubham Pant, MD, MBBS
Is liquid biopsy the game-changer for lung cancer treatment?
0:49
Is liquid biopsy the game-changer for lung cancer treatment?
14 days ago
by
Valsamo Anagnostou, MD, PhD
The Future of Colorectal Cancer Treatment: Refining Patient Selection
0:41
The Future of Colorectal Cancer Treatment: Refining Patient Selection
17 days ago
by
Sara Lonardi, MD

Podcasts

Dr Ligibel on Quality-of-Life Gains From the BWEL Weight Loss Program in Breast Cancer

Dr Ligibel on Quality-of-Life Gains From the BWEL Weight Loss Program in Breast Cancer

Dr Jennifer Ligibel discusses BWEL quality-of-life results, why weight loss differed across groups, insurance barriers, and GLP-1 counseling.

The Patients Missing From Breast Cancer Data

The Patients Missing From Breast Cancer Data

Two researchers explain why Asian American and Hispanic patients with breast cancer are hard to see in the data, and what better data could change.

Beyond the Scan: Predicting Immunotherapy Response With ctDNA in NSCLC

Beyond the Scan: Predicting Immunotherapy Response With ctDNA in NSCLC

Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.

Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC

Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC

Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.

Lung Cancer in Hispanic and Latinx Patients: Risk Factors, Biomarkers, and Clinical Trial Access

Lung Cancer in Hispanic and Latinx Patients: Risk Factors, Biomarkers, and Clinical Trial Access

For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.

Dr Jhaveri on the FDA Approval of Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer

Dr Jhaveri on the FDA Approval of Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer

Komal Jhaveri, MD, discusses the FDA approval of imlunestrant plus abemaciclib for ESR1-mutated breast cancer, EMBER-3 data, and what's next.

Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer

Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

ASTRO 2026 Preview: Dr Raj Singh on De-Escalation, Brain Metastases, and What's Next in Radiation Oncology

ASTRO 2026 Preview: Dr Raj Singh on De-Escalation, Brain Metastases, and What's Next in Radiation Oncology

Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.

Bringing CAR T and Bispecifics to the Community

Bringing CAR T and Bispecifics to the Community

How a community center launches CAR T and bispecific care: managing CRS/ICANS outpatient, closing access gaps, adapting to REMS.

Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic Testing

Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic Testing

Drs Aditya Shreenivas and Razelle Kurzrock break down a 200,000-tumor real-world study on HER2 IHC, ERBB2 alterations, and pan-cancer testing implications.



Targeted Talks

Weight Loss and GLP-1s in Breast Cancer

Targeted Talks

The OncoloGIST

Live from ESMO 2026

The OncoloGIST

Behind the FDA Approval of Imlunestrant/Abemaciclib

Behind the FDA Approval of Imlunestrant/Abemaciclib

ESMO 2026 Coverage

ESMO 2026 Coverage

Community Corner

Community Corner

Continuing Medical Education


All News